Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,407 matching trials from the live ClinicalTrials.gov search.
Conditions
Surgical Site Infection, Vaginal Cuff Cellulitis, Bacterial Vaginosis
Interventions
Clindamycin Vaginal Gel
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Temple, Texas
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

NCT00772928
Conditions
Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
23
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Conditions
Pneumonia, Bacterial
Interventions
Amikacin fosfomycin inhalation solution, Aerosolized placebo
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Completed Not applicable Interventional Accepts healthy volunteers

Multi-site Study of Rapid Diagnostic Syphilis Assays

NCT00300534
Conditions
Syphilis
Interventions
Abbott Laboratories Determine test for syphilis, Investigational syphilis immunochromatographic strip test
Device
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib 1.5% Cream
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Bacterial Infections
Interventions
Information Technology physician assist
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
9,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Reducing Perioperative S. Aureus Transmission

NCT03638947
Conditions
Staphylococcus Aureus, Health Care Associated Infection, Health Care Worker Patient Transmission
Interventions
Swab and decolonization using povidone-iodine cleansing
Device
Lead sponsor
Randy Loftus
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Gonorrhea, Chlamydia, Syphilis
Interventions
On demand doxycycline hyclate 200mg, Daily doxycycline hyclate 100mg, Weekly doxycycline hyclate 100mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Interventions
Cefazolin IV, Linezolid IV, Vancomycin (IV)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland
Conditions
Tuberculosis
Interventions
RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
2 Years and older
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more
Completed Phase 2 Interventional Accepts healthy volunteers

9-valent CRM 197 Pneumococcal

NCT00133549
Conditions
Pneumococcal Infection
Interventions
Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
2
States / cities
Rochester, New York • Cincinnati, Ohio
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Hours to 72 Hours
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vouchers to Promote Tdap Vaccination

NCT01860378
Conditions
Whooping Cough
Interventions
Full price, $5 off
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis

NCT01471457
Conditions
Bacterial Vaginosis
Interventions
Trimo-San gel
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Albuquerque, New Mexico
Conditions
Bacterial Infections
Interventions
[18F]fluoropropyl-trimethoprim
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Conditions
Plague
Interventions
Flagellin/F1/V, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anthrax
Interventions
ETI-204, "Anthim", placebo
Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Infection, Bacteremia, Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 18 Months
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more